English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 20:00 HKT/SGT
Share:
    

Source: ReShape Lifesciences Inc.
ReShape Lifesciences Announces Distribution in Australia

SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
+1-949-429-6680 x106
syoungstrom@reshapelifesci.com

SOURCE: ReShape Lifesciences Inc.

Topic: Press release summary
Source: ReShape Lifesciences Inc.

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
'Balance Beyond the Boom' - HKTDC Entrepreneur Day helps start-ups prepare for the post-pandemic landscape  
Nov 30, 2022 19:00 HKT/SGT
MHI Publishes Integrated Report "MHI Report 2022"  
Wednesday, November 30, 2022 5:07:00 PM
AEON Credit Secures its Framework for Sustainability-Linked Loans, Strengthens and Advances its Sustainability Pledge  
Nov 30, 2022 16:30 HKT/SGT
Mitsubishi Heavy Industries Engineering to be Integrated into MHI  
Wednesday, November 30, 2022 3:02:00 PM
Strong profile bodes well for PRI's entry on the MAI (SET) today  
Nov 30, 2022 15:00 HKT/SGT
NEC Orchestrating Future Fund, an Ecosystem-type CVC Fund, Completes Final Close for US$140 Million  
Wednesday, November 30, 2022 2:15:00 PM
Mitsubishi Power to Upgrade Two Gas Turbines at Tuas Power to Achieve 16.9 kilo-tonnes of Carbon Emissions Reduction Annually  
Wednesday, November 30, 2022 1:55:00 PM
Titan Projects 10x Business Growth for 2022 Partnering with aCommerce in the Philippines  
Nov 30, 2022 12:30 HKT/SGT
Wintermar Offshore (WINS:JK) Acquires 2 Additional AHTS and Celebrates the 12th Anniversary of Listing on IDX  
Nov 30, 2022 12:00 HKT/SGT
Poh Heng Encapsulates Women Empowerment with its Latest Freestyle Collection  
Nov 30, 2022 11:40 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575